Neuromuscular Disorders

Assessing the role of measuring plasma neurofilament light levels in ALS 1:58
Assessing the role of measuring plasma neurofilament light levels in ALS
Nigel Leigh • 17 Mar 2022
Long term safety and efficacy data for ravulizumab in AChR Ab+ generalized myasthenia gravis 2:05
Long term safety and efficacy data for ravulizumab in AChR Ab+ generalized myasthenia gravis
James F. Howard Jr. • 12 Apr 2022
Correlation between synaptic density and cognitive issues in ALS 6:28
Correlation between synaptic density and cognitive issues in ALS
Anna Sanchez Avila • 8 Mar 2022
How can the gut microbiome modulate the peripheral and brain immune systems? 4:45
How can the gut microbiome modulate the peripheral and brain immune systems?
Giulio Pasinetti • 18 Mar 2022
Improving ALS diagnosis: the Gold Coast criteria and the role of TMS 2:44
Improving ALS diagnosis: the Gold Coast criteria and the role of TMS
Matthew Kiernan • 4 Apr 2022
Ex vivo gene therapy for neurodegenerative diseases 2:20
Ex vivo gene therapy for neurodegenerative diseases
Clive Svendsen • 15 Mar 2022
Unanswered questions in ALS research 1:44
Unanswered questions in ALS research
Clive Svendsen • 15 Mar 2022
Phase II and III studies of CNM-Au8 in ALS 1:32
Phase II and III studies of CNM-Au8 in ALS
Robert Glanzman • 13 Oct 2021
Myopathies and gastrointestinal involvement 1:23
Myopathies and gastrointestinal involvement
Marianne de Visser • 28 Sep 2021
Challenges in developing gene-based therapies for neurodegenerative & neuromuscular diseases 3:04
Challenges in developing gene-based therapies for neurodegenerative & neuromuscular diseases
Aida Abu-Baker • 11 Oct 2021
Approved gene-based therapies for neuromuscular diseases 3:57
Approved gene-based therapies for neuromuscular diseases
Aida Abu-Baker • 11 Oct 2021
RNA- and DNA- based therapies for neurodegenerative & neuromuscular diseases 13:42
RNA- and DNA- based therapies for neurodegenerative & neuromuscular diseases
Aida Abu-Baker • 11 Oct 2021
Gene-based therapies for neurodegenerative & neuromuscular diseases 3:23
Gene-based therapies for neurodegenerative & neuromuscular diseases
Aida Abu-Baker • 11 Oct 2021
Differential diagnosis from limb-girdle muscular dystrophies 2:11
Differential diagnosis from limb-girdle muscular dystrophies
Marianne de Visser • 28 Sep 2021
How does C9orf72 expansion impact protein degradation pathways in FTLD and ALS? 4:02
How does C9orf72 expansion impact protein degradation pathways in FTLD and ALS?
Annakaisa Haapasalo • 16 Sep 2021
A novel genetic marker to detect C9orf72 repeat expansion carriers 3:43
A novel genetic marker to detect C9orf72 repeat expansion carriers
Annakaisa Haapasalo • 16 Sep 2021
The content of VJNeurology is intended for healthcare professionals